1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY TYPE OF DISEASE
5.1. Introduction
5.2. Rheumatoid Arthritis
5.3. Osteoarthritis
5.4. Psoriatic Arthritis
5.5. Gout
5.6. Lupus
5.7. Ankylosing Spondylitis
5.8. Others
6. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY DRUG CLASS
6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others
7. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY SALES CHANNEL
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. GLOBAL ANTI-RHEUMATIC DRUG MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Type of Disease
8.2.2. By Drug Class
8.2.3. By Sales Channel
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Type of Disease
8.3.2. By Drug Class
8.3.3. By Sales Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Type of Disease
8.4.2. By Drug Class
8.4.3. By Sales Channel
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Type of Disease
8.5.2. By Drug Class
8.5.3. By Sales Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Type of Disease
8.6.2. By Drug Class
8.6.3. By Sales Channel
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. AbbVie Inc.
10.2. Pfizer Inc.
10.3. Johnson & Johnson
10.4. Amgen Inc.
10.5. Novartis AG
10.6. Eli Lilly and Company
10.7. Bristol Myers Squibb
10.8. Merck & Co., Inc.
10.9. Roche Holding AG
10.10. GlaxoSmithKline plc
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES